Developer docs
API playgroundTry for free, no card

Search company profiles

FDAnews

Full company profile

uuid002gkh6

Namestring
FDAnews
Legal namestring
CenterWatch
Websiteurl
fdanews.com
Company typeenum
Private
Founded yearint
1972
Descriptiontext

FDAnews is a private, for-profit information services company founded in 1972 that operates as a specialized publisher of domestic and international regulatory, legislative, and business news focused on the U.S. Food and Drug Administration and adjacent life sciences regulatory environments. The company is headquartered in Falls Church, Virginia, with an additional office presence in Cary, North Carolina (5000 Centregreen Way, Suite 200), and operates with a headcount in the 11-50 range. Its legal entity appears to be CenterWatch, suggesting FDAnews functions as a brand or division within a broader entity.

The company's core product is regulatory intelligence — news, analysis, and tracking of FDA rulemaking, enforcement, and policy developments — delivered to life sciences and medical product companies whose regulatory affairs, compliance, and quality functions depend on timely awareness of agency activity. An adjacent offering, the clinical trials listings platform, indexes more than 40,000 clinical trial listings searchable by medical condition, therapeutic area, and location, extending the company's reach into clinical research operations and patient recruitment audiences.

The business model is consistent with a subscription-based B2B information services publisher: recurring fees from professionals and organizations needing continuous regulatory monitoring and reference content. The company has been bootstrapped through its 52-year operating history with no disclosed funding rounds, and operates without disclosed product leadership, AI capabilities, mobile applications, or API integrations in the available data. The founder, David Swit, is the only identified leadership figure, indicating either a lean organizational structure or that additional management details were not captured in the source data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFalls Church, United States
HQ citystring
Falls Church
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
FDA regulatory news, pharmaceutical regulatory intelligence, medical device compliance, healthcare legislative updates, regulatory business information
Industry2 codes
1Regulatory Affairs, Labeling & Advertising/Promotion Compliance
CodeHLAJADAIPrimaryYes
2Clinical Trials Authorization & Oversight (GCP)
CodeHLAJADAFPrimaryNo
NAICS code1 code
  • Broadcasting and Content Providers516
Product category
Regulatory Intelligence and News
No data
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

FDAnews is a provider of domestic and international regulatory, legislative, and business news aimed at organizations in FDA-regulated industries. The company delivers news, analysis, and information services to professionals in pharmaceutical, medical device, biotechnology, and related sectors. Based on its 1972 founding, the firm has operated as a long-standing information source for the FDA-regulated community.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1FDA Regulatory and Business News Service
CategoryRegulatory News and Intelligence
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Advarra provides IRB, clinical-research, and regulatory compliance services to pharma, biotech, and CROs. While more services- than content-focused, it competes with FDAnews's CenterWatch-adjacent offering by serving the same clinical-research and regulatory-affairs buyer with integrated compliance solutions.

TypeDirect peer
Description

BioPharma Dive is a B2B news outlet covering biopharma industry developments including FDA decisions, clinical trials, and policy. It targets overlapping pharmaceutical and biotech decision-makers and competes directly with FDAnews's regulated-industry news positioning.

TypeDirect peer
Description

Citeline, an Informa business, publishes the Pink Sheet and other long-established regulatory intelligence franchises covering FDA and global drug regulation. It directly competes with FDAnews on premium regulatory intelligence subscriptions and also operates clinical-trial databases analogous to CenterWatch.

TypeDirect peer
Description

RAPS is the leading professional society for regulatory affairs professionals, publishing Regulatory Focus and providing regulatory intelligence, training, and certification. It directly competes with FDAnews for the same regulatory-affairs reader audience and offers overlapping news, analysis, and educational content.

TypeDirect peer
Description

Pharmaceutical Technology is an industry news and analysis outlet covering drug development, manufacturing, and regulation. It serves an overlapping pharma audience and competes with FDAnews for attention on regulatory and industry-business news.

TypeDirect peer
Description

Fierce Pharma is a widely-read B2B pharma news outlet covering FDA approvals, policy, and industry business news. It serves an overlapping audience of pharma executives and regulatory professionals and competes directly with FDAnews for attention and subscription dollars.

TypeBroad incumbent
Description

Clarivate provides regulatory intelligence, clinical-trial data (Cortellis), and IP analytics to pharma and biotech. Its regulatory intelligence offerings (e.g., formerly DRG) directly overlap with FDAnews's regulated-industry intelligence value proposition as part of a much broader analytics portfolio.

TypeBroad incumbent
Description

Veeva is a leading life-sciences cloud platform whose Veeva Vault RIM suite handles regulatory information management for major pharma companies. It represents a software-driven competitive threat to FDAnews's traditional regulatory intelligence content, embedding regulatory workflows inside enterprise platforms.

TypeDirect peer
Description

DIA is a global, member-based organization that disseminates regulatory and scientific information across the drug-development lifecycle, including conferences, publications, and educational resources. It overlaps with FDAnews in providing regulatory intelligence and serves many of the same pharmaceutical and biotech professionals.

TypeBroad incumbent
Description

Wolters Kluwer operates a broad portfolio of regulatory and compliance information products (including Lippincott, Medi-Span, and OneSumX for regulatory reporting). It is a much larger incumbent that competes with FDAnews across multiple pharma regulatory and compliance information segments through integrated software platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FDAnews

Regulatory Intelligence and Newsfdanews.com

What FDAnews does

FDAnews is a private, for-profit information services company founded in 1972 that operates as a specialized publisher of domestic and international regulatory, legislative, and business news focused on the U.S. Food and Drug Administration and adjacent life sciences regulatory environments. The company is headquartered in Falls Church, Virginia, with an additional office presence in Cary, North Carolina (5000 Centregreen Way, Suite 200), and operates with a headcount in the 11-50 range. Its legal entity appears to be CenterWatch, suggesting FDAnews functions as a brand or division within a broader entity.

The company's core product is regulatory intelligence — news, analysis, and tracking of FDA rulemaking, enforcement, and policy developments — delivered to life sciences and medical product companies whose regulatory affairs, compliance, and quality functions depend on timely awareness of agency activity. An adjacent offering, the clinical trials listings platform, indexes more than 40,000 clinical trial listings searchable by medical condition, therapeutic area, and location, extending the company's reach into clinical research operations and patient recruitment audiences.

The business model is consistent with a subscription-based B2B information services publisher: recurring fees from professionals and organizations needing continuous regulatory monitoring and reference content. The company has been bootstrapped through its 52-year operating history with no disclosed funding rounds, and operates without disclosed product leadership, AI capabilities, mobile applications, or API integrations in the available data. The founder, David Swit, is the only identified leadership figure, indicating either a lean organizational structure or that additional management details were not captured in the source data.

FDAnews firmographics

Firmographics
Name
FDAnews
Legal name
CenterWatch
Website
https://fdanews.com
Company type
Private
Founded year
1972
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

FDAnews industry classification

Industry
Product category
Regulatory Intelligence and News
NAICS
Broadcasting and Content Providers (516)
akta.pro primary industry
Regulatory Affairs, Labeling & Advertising/Promotion Compliance (HLAJADAI)
akta.pro secondary industry
Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)

Keywords

  • FDA regulatory news
  • Pharmaceutical regulatory intelligence
  • Medical device compliance
  • Healthcare legislative updates
  • Regulatory business information

Where FDAnews is headquartered

Location

Headquarters

HQ city
Falls Church
HQ country
United States
HQ region
North America

Offices1 record

Markets served

FDAnews business model

Business model
GTM type
B2B
Offering type
Digital Commerce or Content
Cost components
Personnel, Operations, Marketing or Sales

FDAnews product offering

Product offering

Core offering

FDAnews is a provider of domestic and international regulatory, legislative, and business news aimed at organizations in FDA-regulated industries. The company delivers news, analysis, and information services to professionals in pharmaceutical, medical device, biotechnology, and related sectors. Based on its 1972 founding, the firm has operated as a long-standing information source for the FDA-regulated community.

Differentiator

Problem solved

Functional benefit

Products and services

  • FDA Regulatory and Business News Service

Companies that use FDAnews

Customer profile

Ideal customer profiles1 record

FDAnews technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

FDAnews partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

FDAnews competitors and assessment

Company assessment

Emerging players

  • Advarra: Advarra provides IRB, clinical-research, and regulatory compliance services to pharma, biotech, and CROs. While more services- than content-focused, it competes with FDAnews's CenterWatch-adjacent offering by serving the same clinical-research and regulatory-affairs buyer with integrated compliance solutions.

Direct peers

  • BioPharma Dive: BioPharma Dive is a B2B news outlet covering biopharma industry developments including FDA decisions, clinical trials, and policy. It targets overlapping pharmaceutical and biotech decision-makers and competes directly with FDAnews's regulated-industry news positioning.
  • Citeline (Informa): Citeline, an Informa business, publishes the Pink Sheet and other long-established regulatory intelligence franchises covering FDA and global drug regulation. It directly competes with FDAnews on premium regulatory intelligence subscriptions and also operates clinical-trial databases analogous to CenterWatch.
  • Regulatory Affairs Professionals Society (RAPS): RAPS is the leading professional society for regulatory affairs professionals, publishing Regulatory Focus and providing regulatory intelligence, training, and certification. It directly competes with FDAnews for the same regulatory-affairs reader audience and offers overlapping news, analysis, and educational content.
  • Pharmaceutical Technology: Pharmaceutical Technology is an industry news and analysis outlet covering drug development, manufacturing, and regulation. It serves an overlapping pharma audience and competes with FDAnews for attention on regulatory and industry-business news.
  • Fierce Pharma: Fierce Pharma is a widely-read B2B pharma news outlet covering FDA approvals, policy, and industry business news. It serves an overlapping audience of pharma executives and regulatory professionals and competes directly with FDAnews for attention and subscription dollars.
  • Drug Information Association (DIA): DIA is a global, member-based organization that disseminates regulatory and scientific information across the drug-development lifecycle, including conferences, publications, and educational resources. It overlaps with FDAnews in providing regulatory intelligence and serves many of the same pharmaceutical and biotech professionals.

Broad incumbents

  • Clarivate: Clarivate provides regulatory intelligence, clinical-trial data (Cortellis), and IP analytics to pharma and biotech. Its regulatory intelligence offerings (e.g., formerly DRG) directly overlap with FDAnews's regulated-industry intelligence value proposition as part of a much broader analytics portfolio.
  • Veeva Systems: Veeva is a leading life-sciences cloud platform whose Veeva Vault RIM suite handles regulatory information management for major pharma companies. It represents a software-driven competitive threat to FDAnews's traditional regulatory intelligence content, embedding regulatory workflows inside enterprise platforms.
  • Wolters Kluwer: Wolters Kluwer operates a broad portfolio of regulatory and compliance information products (including Lippincott, Medi-Span, and OneSumX for regulatory reporting). It is a much larger incumbent that competes with FDAnews across multiple pharma regulatory and compliance information segments through integrated software platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

FDAnews financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FDAnews leadership team

Management profile

Number of profiles

Profiles1 record

FDAnews funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FDAnews M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FDAnews

What does FDAnews do?

FDAnews is a provider of domestic and international regulatory, legislative, and business news aimed at organizations in FDA-regulated industries. The company delivers news, analysis, and information services to professionals in pharmaceutical, medical device, biotechnology, and related sectors. Based on its 1972 founding, the firm has operated as a long-standing information source for the FDA-regulated community.

When was FDAnews founded?

FDAnews was founded in 1972. It employs 11 to 50 people.

Where is FDAnews based?

FDAnews is headquartered in Falls Church, United States, in the North America region.

Who are FDAnews's main competitors?

Advarra is listed as an emerging player. Direct peers are BioPharma Dive, Citeline (Informa), Regulatory Affairs Professionals Society (RAPS), Pharmaceutical Technology, Fierce Pharma and Drug Information Association (DIA). Broad incumbents are Clarivate, Veeva Systems and Wolters Kluwer.

Does FDAnews have an API?

No public API is recorded for FDAnews.

What industry is FDAnews in?

FDAnews's product category is Regulatory Intelligence and News. Its primary akta.pro industry code is HLAJADAI, Regulatory Affairs, Labeling & Advertising/Promotion Compliance, with a secondary code of HLAJADAF, Clinical Trials Authorization & Oversight (GCP). Its NAICS code is 516.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketBeatCapricor Highlights Two-Year Deramiocel Data as FDA Decision NearsCapricor presented two-year HOPE-3 data for deramiocel in Duchenne muscular dystrophy, showing a 4.55% improvement in upper-limb function versus placebo. The FDA extended its review deadline to Nov. 22, and the company plans to explore development in younger patients and other regions.AETOSWireBeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEAThe U.S. FDA approved TEVIMBRA plus ZIIHERA and chemotherapy for first-line treatment of HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinoma. The regimen showed median overall survival of 26.4 months versus 19.2 months in the control arm, with benefits across PD-L1 subgroups.Global Regulatory Solutions and Services CompanyGlobal Regulatory Requirements in PharmacovigilanceA blog post outlines pharmacovigilance regulatory requirements across the United States, European Union, Japan, and international bodies, covering FDA 21 CFR Part 314, EMA EudraVigilance, PMDA GVP Ordinance, ICH E2E and E2B(R3), and WHO VigiBase. It recommends best practices including quality systems, SOPs, adverse event reporting, regulatory correspondence, and automation.Outsourced PharmaAI Integration In Drug Manufacturing: GMP Insights For Operational Excellence, Regulatory ComplianceA Sidley Austin LLP guest column published June 4, 2024 outlines how AI and machine learning are being applied in drug manufacturing, citing use cases in aseptic processing, environmental monitoring, chromatography and injectable visual inspection. It notes regulatory lag, pointing to the EU AI Act, EMA draft guidance expected in the second half of 2024, and FDA discussion papers. The authors recommend five compliance factors: data integrity, explainability, validation, risk management and staff training.MesalabsCap Torque Testing: Standards and Regulations You Need to KnowA technical article outlines cap torque testing standards and regulations across pharmaceutical, chemical, food and beverage, and cosmetics industries, covering ASTM D7860-14, D3475-20 and D3474-23, ISBT, ISO 13127 and ISO 17025, plus FDA, OSHA, USCPSC, DOT and EPA rules. It also notes the EU's Single-Use Plastics Directive requiring tethered caps on single-use plastic beverage containers up to three liters from July 2024.FdanewsFDAnews.com Information & LinksFDAnews.com has ceased production of its publications and databases, effectively closing its operations. The entity invites readers with questions regarding legacy content to contact customer service via email.GlobeNewswireMyovant Sciences Announces FDA Approval ofThe FDA approved ORGOVYX (relugolix) for advanced prostate cancer, the first oral GnRH receptor antagonist for this indication. The Phase 3 HERO study showed 96.7% testosterone suppression to castrate levels through 48 weeks, versus 88.8% for leuprolide. The drug is expected to be available in January 2021.PackaginglawWhat are FDA Regulations Concerning UV Coatings?A legal Q&A explains that UV coatings on paper cups may require FDA clearance for food and beverage contact, depending on migration potential and mouth contact risk. FDA addressed UV formulations under Food Contact Notification 772, effective 2008, which clears certain UV or electronic beam coatings on polymeric, paper, paperboard and metal substrates when migration limits are met. Only RadTech Food Packaging Alliance members and their customers may use FCN 772 materials.PR NewswireFDAnews Joins WIRB-Copernicus GroupWIRB-Copernicus Group (WCG) announced the acquisition of FDAnews, a provider of global regulatory information for the clinical research, biopharmaceutical, and medical device industries. FDAnews will join CenterWatch, WCG's existing clinical trial publishing business, to form a combined publishing division operating independently within the group. WCG stated it will support the new FDAnews/CenterWatch division with capital, expertise, and corporate operational support as it expands its offerings across the life science ecosystem.GlobeNewswireUltragenyx Provides Regulatory Update on Burosumab (KRN23)Ultragenyx reached an FDA agreement on the clinical data package for its burosumab (KRN23) BLA filing for X-linked hypophosphatemia, with both pediatric and adult indications included. The FDA agreed that pediatric data from Studies CL201 and CL205 would suffice, and the BLA is planned for the second half of 2017.